Sanford C. Bernstein started coverage on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a research report released on Thursday, Marketbeat Ratings reports. The brokerage issued a market perform rating and a $72.00 price target on the biopharmaceutical company’s stock.

RARE has been the topic of several other research reports. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a report on Tuesday, June 20th. Stifel Nicolaus reiterated a buy rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 30th. Zacks Investment Research downgraded shares of Ultragenyx Pharmaceutical from a hold rating to a sell rating in a report on Tuesday, July 11th. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a report on Thursday, June 22nd. Finally, Morgan Stanley cut their price target on shares of Ultragenyx Pharmaceutical from $84.00 to $79.00 and set an equal weight rating on the stock in a report on Monday, May 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $84.67.

Shares of Ultragenyx Pharmaceutical (RARE) traded down 0.814% during trading on Thursday, reaching $66.445. 42,010 shares of the company’s stock traded hands. The company has a 50 day moving average price of $64.61 and a 200-day moving average price of $67.72. The stock’s market cap is $2.82 billion. Ultragenyx Pharmaceutical has a one year low of $51.67 and a one year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same quarter last year, the company posted ($1.46) earnings per share. On average, equities research analysts expect that Ultragenyx Pharmaceutical will post ($7.05) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/ultragenyx-pharmaceutical-inc-nasdaqrare-coverage-initiated-by-analysts-at-sanford-c-bernstein/1464027.html.

In other news, VP Theodore Alan Huizenga sold 480 shares of the stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $57.46, for a total transaction of $27,580.80. Following the transaction, the vice president now owns 9,366 shares in the company, valued at approximately $538,170.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 9.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Fortaleza Asset Management Inc. raised its position in shares of Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 980 shares during the period. Pacer Advisors Inc. raised its position in shares of Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 560 shares during the period. Strs Ohio raised its position in shares of Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 300 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 115 shares during the period. Finally, Massmutual Trust Co. FSB ADV acquired a new position in shares of Ultragenyx Pharmaceutical during the first quarter worth about $237,000. Hedge funds and other institutional investors own 95.32% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.